JP2023542453A - Sars-cov-2阻害剤 - Google Patents

Sars-cov-2阻害剤 Download PDF

Info

Publication number
JP2023542453A
JP2023542453A JP2023502638A JP2023502638A JP2023542453A JP 2023542453 A JP2023542453 A JP 2023542453A JP 2023502638 A JP2023502638 A JP 2023502638A JP 2023502638 A JP2023502638 A JP 2023502638A JP 2023542453 A JP2023542453 A JP 2023542453A
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
seq
acid sequence
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023502638A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542453A5 (https=
JPWO2022015418A5 (https=
Inventor
カオ,ロンシン
コベントリー,ブライアン
ゴレシュニク,インナ
ミラー,ローレン
ベイカー,デイビッド
コソドイ,リサ
ボーウェン,ジョン
カーター,ローレン
ケース,ジェームズ,ブレット
ダイアモンド,マイケル
エドマン,ナターシャ
ハント,アンドリュー
ジュウェット,マイケル,クリストファー
オゴハラ,カサンドラ,ジーン
パク,ヤン-ジュン
ラヴィチャンドラン,ラシュミ
スチュアート,ランス,ジョセフ
ヴィースラー,デイビッド
ヴォーゲリ,バスティアン
ウォールズ,アレクサンドラ,シー.
ウー,ケジア
ボイケン,スコット
ウエダ,ジョージ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St Louis WUSTL filed Critical Washington University in St Louis WUSTL
Publication of JP2023542453A publication Critical patent/JP2023542453A/ja
Publication of JP2023542453A5 publication Critical patent/JP2023542453A5/ja
Publication of JPWO2022015418A5 publication Critical patent/JPWO2022015418A5/ja
Priority to JP2025136537A priority Critical patent/JP2025170319A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
JP2023502638A 2020-07-14 2021-05-25 Sars-cov-2阻害剤 Pending JP2023542453A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025136537A JP2025170319A (ja) 2020-07-14 2025-08-19 Sars-cov-2阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063051474P 2020-07-14 2020-07-14
US63/051,474 2020-07-14
US202063067593P 2020-08-19 2020-08-19
US63/067,593 2020-08-19
PCT/US2021/034069 WO2022015418A1 (en) 2020-07-14 2021-05-25 Sars-cov-2 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025136537A Division JP2025170319A (ja) 2020-07-14 2025-08-19 Sars-cov-2阻害剤

Publications (3)

Publication Number Publication Date
JP2023542453A true JP2023542453A (ja) 2023-10-10
JP2023542453A5 JP2023542453A5 (https=) 2024-06-03
JPWO2022015418A5 JPWO2022015418A5 (https=) 2024-06-03

Family

ID=76808129

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023502638A Pending JP2023542453A (ja) 2020-07-14 2021-05-25 Sars-cov-2阻害剤
JP2025136537A Pending JP2025170319A (ja) 2020-07-14 2025-08-19 Sars-cov-2阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025136537A Pending JP2025170319A (ja) 2020-07-14 2025-08-19 Sars-cov-2阻害剤

Country Status (7)

Country Link
US (1) US20230250134A1 (https=)
EP (1) EP4182027A1 (https=)
JP (2) JP2023542453A (https=)
KR (1) KR20230038485A (https=)
CN (1) CN116209672A (https=)
AU (1) AU2021308208A1 (https=)
WO (1) WO2022015418A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240309059A1 (en) * 2021-07-07 2024-09-19 National University Corporation Tokyo Medical And Dental University Peptide having anti-viral activity, anti-viral agent comprising said peptide, and method for producing said anti-viral agent
KR20240177843A (ko) * 2023-06-20 2024-12-30 주식회사 엔큐라젠 SARS-CoV-2스파이크 단백질에 특이적으로 결합하는 펩타이드 및 이의 용도
WO2025101453A1 (en) * 2023-11-07 2025-05-15 University Of Washington De novo design of potent minibinder antagonists of il-6r, gp130, and il1-r1
WO2025221716A1 (en) * 2024-04-17 2025-10-23 University Of Washington Smart mhc: a de-novo designed platform for soluble expression of peptide-receptive class-i mhc in e. coli

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098448A1 (en) * 2001-06-04 2002-12-12 Human Genome Sciences, Inc. Methods and compositions for modulating ace-2 activity
KR20230017215A (ko) * 2020-05-27 2023-02-03 유니버시티 오브 워싱턴 드 노보 설계한 단백질 스위치에 기반한 모듈형의 일반화 가능한 바이오센서 플랫폼

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHANG G ET AL.: "The first-in-class peptide binder to the SARS-CoV-2 spike protein", BIORXIV [ONLINE], JPN6025020251, 20 March 2020 (2020-03-20), ISSN: 0005597557 *

Also Published As

Publication number Publication date
AU2021308208A1 (en) 2023-01-05
US20230250134A1 (en) 2023-08-10
CN116209672A (zh) 2023-06-02
JP2025170319A (ja) 2025-11-18
EP4182027A1 (en) 2023-05-24
KR20230038485A (ko) 2023-03-20
WO2022015418A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
JP2023542453A (ja) Sars-cov-2阻害剤
JP7094103B2 (ja) インフルエンザウイルスワクチンおよびその使用
JP6643981B2 (ja) インフルエンザウイルスワクチンおよびその使用
JP6735269B2 (ja) インフルエンザウイルスワクチンおよびその使用
CN105073196B (zh) 呼吸道合胞病毒f蛋白表位
JP4902352B2 (ja) トランスフォーミング増殖因子β1(TGF−β1)との結合能を有するペプチド
WO2021170131A1 (zh) 可溶性ace2和融合蛋白,及其应用
JP2022530439A (ja) 組換えインフルエンザ抗原
CN113785052B (zh) 新重组二胺氧化酶及其治疗以过量组胺为特征的疾病的用途
CN115785232A (zh) 用于预防或治疗冠状病毒感染的融合蛋白、Spike蛋白纳米颗粒及其应用
CZ303409B6 (cs) Zkrácený a mutovaný lidský chemokin
WO2026021236A1 (zh) 可抑制类mers冠状病毒感染的多肽及其应用
CA3181996A1 (en) Sars-cov-2 inhibitors
WO2024229151A2 (en) Multimeric coronavirus binding molecules and uses thereof
CN115925892A (zh) 一种抗新型冠状病毒的中和抗体d9及其应用
CN117043176A (zh) 抗感染双环肽配体
US10766929B2 (en) De novo designed hemagglutinin binding proteins
CA3153354A1 (en) Computational design of alpha(v) beta (6) integrin binding proteins
JP2022536797A (ja) 炎症性状態を処置するための方法および組成物
JP2022508619A (ja) ニューロメジンペプチドを使用して2型サイトカイン媒介性炎症を低減させる方法
CN115925893B (zh) 一种抗新型冠状病毒的中和抗体d7及其应用
US12098175B2 (en) Peptide inhibitors targeting the CXCL12/HMGB1 interaction and uses thereof
WO2025101453A1 (en) De novo design of potent minibinder antagonists of il-6r, gp130, and il1-r1
WO2025250851A1 (en) Trivalent pan-sarbecovirus mucosal vaccine constructs and methods of making and using same
US20230365640A1 (en) Clec2 fusion protein and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250520

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251111